We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
+4.23%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.4B
AUM Growth
-$764M
(-24%)
Cap. Flow
-$999M
Cap. Flow
% of AUM
-41.57%
Top 10 Holdings %
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tempest Therapeutics
TPST
|
+$94.4M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$24M |
| 3 |
AGN
Allergan plc
AGN
|
+$13.8M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$11.9M |
| 5 |
MBLY
Mobileye N.V.
MBLY
|
+$8.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$42.1M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
+$27.4M |
| 3 |
AstraZeneca
AZN
|
+$13.5M |
| 4 |
Gilead Sciences
GILD
|
+$11.5M |
| 5 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$11.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 88.65% |
| 2 | Healthcare | 9.88% |
| 3 | Technology | 0.55% |
| 4 | Energy | 0.39% |
| 5 | Industrials | 0.26% |
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q1 2015 Portfolio in Review
As of Q1 2015, Sabby Management held 367 positions worth $2.4B, down 24% from $3.17B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Sabby Management withdrew a net $999M in Q1 2015, closing 85 positions and reducing 66 holdings. Its most notable exit was Pfizer, an estimated $42.1M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 89% of assets, down from 90% a quarter earlier, followed by Healthcare and Technology.
Against the trend, Sabby Management opened a new position in Tempest Therapeutics worth $4.69M.
- Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
- Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
- Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
- Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
- Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
- Sabby Management opened 126 new positions and closed 85 in Q1 2015.
- Sabby Management's portfolio value fell 24% quarter-over-quarter to $2.4B.
Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.